STOCK TITAN

Senseonics Holdings (SENS) Stock News

SENS NASDAQ

Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.

Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.

Rhea-AI Summary

Senseonics (SENS) and Beta Bionics (BBNX) commercially launched the integration of Eversense 365 with the iLet Bionic Pancreas for diabetes management. The launch meets the companies’ previously announced Q4 2026 timeline, following their partnership announcement in September 2026.

The integrated system combines Eversense 365, an implantable continuous glucose monitor designed for up to 365 days of use, with iLet’s automated insulin delivery. iLet uses glucose data and an adaptive algorithm to determine insulin doses without carbohydrate counting or manual correction doses, although users must remain carbohydrate aware. The companies also committed to a future integration of Eversense 365 with Mint, Beta Bionics’ tubeless patch pump; they expect that integration to broaden insulin delivery options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
none
-
Rhea-AI Summary

Senseonics Holdings (SENS) reported third-quarter 2026 revenue of $19.6 million, up approximately 140% year over year, and raised its annual outlook. U.S. revenue reached $16.8 million, while revenue outside the U.S. was $2.8 million. Gross margin rose to approximately 62% from 43%. Net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43 per share.

The company raised full-year revenue guidance to $68 million–$70 million from $62 million–$66 million and gross margin guidance to more than 60% from 58%–61%. Its Beta Bionics partnership targets an Eversense 365 integration with the iLet insulin delivery system, with launch planned for the fourth quarter of 2026, subject to integration activities and applicable requirements. Senseonics also initiated the first-in-human study of its investigational Freedom glucose monitoring system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
-
Rhea-AI Summary

Senseonics Holdings (NASDAQ: SENS) initiated its first-in-human clinical study of Freedom, an investigational continuous glucose monitoring system designed without an on-body transmitter.

The early feasibility study will evaluate clinical safety and device functionality, including direct Bluetooth communication with a mobile device. Freedom is designed for one-year sensing. Senseonics expects to initiate a pivotal study in 2027 and targets a potential commercial launch in 2028. Preclinical studies completed in the second quarter of 2026 identified a preferred antenna configuration and implantation approach for human evaluation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
none
Rhea-AI Summary

Senseonics Holdings (NASDAQ: SENS) management will participate in two investor conferences in New York on November 10 and 11, 2026.

Management will hold a fireside chat at the Stifel 2026 Healthcare Conference at 3:20 pm ET on November 10 and present at the Canaccord Genuity MedTech, Diagnostics & Digital Health Forum at 10:30 am ET on November 11. Management will also host one-on-one investor meetings at both events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
conferences
-
Rhea-AI Summary

Senseonics Holdings (NASDAQ: SENS) plans to release its third-quarter 2026 financial results after market close on November 9, 2026. Management will review the quarter’s performance on a conference call at 4:30 p.m. Eastern Time that day. The call will also be webcast, with an archive available on the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
conferences earnings date
-
Rhea-AI Summary

Senseonics (SENS) and Beta Bionics (BBNX) have formed a strategic partnership to integrate the year-long Eversense® 365 continuous glucose monitoring system with the iLet® Bionic Pancreas automated insulin delivery platform.

The integrated system is intended to pair implantable, up-to-365-day glucose sensing with fully adaptive insulin dosing that does not require carb counting*, aiming to simplify diabetes management and broaden AID choices for adults with diabetes. Senseonics expects development of the Eversense 365–iLet integration to be completed in the fourth quarter of 2026, with commercial launch planned thereafter, subject to required testing, validation and applicable regulatory requirements. Interested individuals can sign up to receive updates and information on potential early access opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
partnership
Rhea-AI Summary

Senseonics (SENS) will participate in two institutional investor conferences in New York in September 2026.

Management will host one-on-one investor meetings at the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference on September 10, 2026. At the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026, management will present at 3:00 pm ET on Monday, September 14, and also hold one-on-one meetings with investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.80%
Tags
none
-
Rhea-AI Summary

Senseonics (NASDAQ: SENS) reported second quarter 2026 revenue of $14.5 million, up approximately 120% year-over-year, with U.S. revenue of $12.6 million growing more than 150%. Gross margin improved to about 59%, versus 47% a year earlier.

Net loss widened to $36.7 million, or $0.63 per share, compared to a $14.5 million loss, or $0.36 per share, in Q2 2025, driven by higher R&D and SG&A expenses related to Gemini and Freedom development and commercial integration. Cash, restricted cash and short-term investments totaled about $143 million at June 30, 2026, with long-term debt of roughly $55.8 million.

According to Senseonics, full-year 2026 revenue guidance was raised to $62–$66 million and gross margin guidance to 58–61%. The company completed the transition of European Eversense commercialization in-house and expanded its Eon Care nursing network to over 90 nurses, now handling around 40% of insertion procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.31%
Tags
-
Rhea-AI Summary

Senseonics (NASDAQ: SENS) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day, accessible via the company’s Investor Relations website and by phone using the provided dial-in numbers and passcode.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences earnings date
Rhea-AI Summary

Senseonics (NYSE:SENS) and Welldoc announced a strategic partnership to develop a next-generation Eversense 365 mobile app for diabetes management.

The new app will keep current features while adding enhanced user experience, deeper integration with digital health tools, and planned U.S. launch in the second half of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
partnership

FAQ

What is the current stock price of Senseonics Holdings (SENS)?

Senseonics Holdings (SENS) last closed at $8.91.

What is the market cap of Senseonics Holdings (SENS)?

The market cap of Senseonics Holdings (SENS) is approximately $487.8M.